A carregar...
Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
The treatment of hepatitis C virus has changed dramatically with the rapid advent of numerous new antiviral agents, including direct-acting antivirals and agents with non-viral targets (cyclophilin inhibitors, interferon-lambda, vaccine therapy). Given the better safety profile and high antiviral po...
Na minha lista:
| Publicado no: | Hepat Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4786064/ https://ncbi.nlm.nih.gov/pubmed/27019602 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/HMER.S62014 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|